Home » Stocks » FBIO

Fortress Biotech, Inc. (FBIO)

Stock Price: $3.54 USD 0.09 (2.61%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $3.45 -0.09 (-2.54%) Jan 22, 7:52 PM
Market Cap 335.60M
Revenue (ttm) 42.98M
Net Income (ttm) -56.72M
Shares Out 76.09M
EPS (ttm) -0.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $3.54
Previous Close $3.45
Change ($) 0.09
Change (%) 2.61%
Day's Open 3.40
Day's Range 3.40 - 3.56
Day's Volume 623,935
52-Week Range 1.14 - 4.78

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 day ago

NEW YORK, Jan. 23, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 20...

Business Wire - 2 days ago

LOS ANGELES--(BUSINESS WIRE)---- $FBIO #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fortress Biotech, Inc. (FBIO)

PRNewsWire - 2 days ago

LOS ANGELES, Jan. 22, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fortress Biotech, Inc. ("F...

Newsfile Corp - 3 days ago

New York, New York--(Newsfile Corp. - January 20, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress" or the "Company") (NASDA...

Newsfile Corp - 6 days ago

New York, New York--(Newsfile Corp. - January 18, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) betwe...

Newsfile Corp - 1 week ago

New York, New York--(Newsfile Corp. - January 11, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) betwe...

PRNewsWire - 2 weeks ago

NEW YORK, Jan. 9. 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 201...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - January 6, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) betwee...

GlobeNewsWire - 2 weeks ago

NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...

PRNewsWire - 3 weeks ago

NEW YORK, Jan. 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress" or the "Company") (NASDAQ: FBIO) and certai...

PRNewsWire - 3 weeks ago

LOS ANGELES, Dec. 30, 2020 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fortress Biotech, Inc. ("F...

Business Wire - 3 weeks ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and Octobe...

Newsfile Corp - 4 weeks ago

New York, New York--(Newsfile Corp. - December 26, 2020) - Pomerantz LLP announces that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress" or the "Company") (NASD...

Newsfile Corp - 4 weeks ago

New York, New York--(Newsfile Corp. - December 26, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) bet...

PRNewsWire - 1 month ago

NEW YORK, Dec. 17, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 20...

The Motley Fool - 1 month ago

One of the company's subsidiaries announced some good news today.

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - December 15, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fortress Biotech, Inc. ("For...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - December 14, 2020) - Pomerantz LLP announces that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress" or the "Company") (NASD...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - December 13, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) betw...

Business Wire - 1 month ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $FBIO #CLASSACTION--Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in Class Action Lawsuit Against Fortress Biotech,...

Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress Biotech" or "the Company")...

Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and Octobe...

Business Wire - 1 month ago

LOS ANGELES--(BUSINESS WIRE)---- $FBIO #classaction--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or o...

PRNewsWire - 1 month ago

NEW YORK, Dec. 5, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Fortress B...

Business Wire - 1 month ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $FBIO #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fortress Biotech, Inc. (FBI...

Business Wire - 1 month ago

SAN DIEGO & NEW YORK--(BUSINESS WIRE)---- $FBIO #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Fortress Biotech, Inc. (NASDAQ: FBIO) filed a class action c...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - December 3, 2020) -  Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the secu...

Business Wire - 1 month ago

LOS ANGELES--(BUSINESS WIRE)---- $FBIO #classaction--The Law Offices of Frank R. Cruz announces an investigation of Fortress Biotech, Inc. (“Fortress” or the “Company”) (NASDAQ: FBIO) on behal...

Business Wire - 1 month ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $FBIO #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fortress Biotech, Inc. (FBIO) on Behalf of Investors

Business Wire - 1 month ago

LOS ANGELES--(BUSINESS WIRE)---- $FBIO #FBIO--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fortress Biotech, Inc.

Business Wire - 1 month ago

LOS ANGELES--(BUSINESS WIRE)---- $FBIO #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Fortress Biotech, Inc. (FBIO) on Behalf of Inv...

Business Wire - 1 month ago

LOS ANGELES--(BUSINESS WIRE)---- $FBIO #FBIO--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fortress Biotech, Inc.

Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Fortress Biotech, Inc....

PRNewsWire - 1 month ago

NEW YORK, Nov. 27, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress" or the "Company") (NASDAQ: FBIO) and certa...

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...

Seeking Alpha - 2 months ago

Fortress Bio controls a network of companies that are engaged in drug development activities. The company identifies early stage assets, and helps to develop them, guide them through the clini...

Zacks Investment Research - 2 months ago

Fortress Biotech (FBIO) delivered earnings and revenue surprises of 28.57% and -14.31%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the...

GlobeNewsWire - 2 months ago

Product revenue for the first nine months of 2020 increased 29 % year-over-year to $ 30.8 million

GlobeNewsWire - 2 months ago

Clinical data on CAEL-101 for AL amyloidosis and MB-106 CD20-targeted CAR T cell therapy to be presented Clinical data on CAEL-101 for AL amyloidosis and MB-106 CD20-targeted CAR T cell therap...

Zacks Investment Research - 2 months ago

Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 3 months ago

Fortress Biotech (FBIO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GlobeNewsWire - 3 months ago

NEW YORK, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...

Zacks Investment Research - 3 months ago

Fortress Biotech has been struggling lately, but the selling pressure may be coming to an end soon.

PRNewsWire - 3 months ago

NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fortress Biotech, Inc. ("Fortress Biotech" or the "Company") (NASDAQ: FBIO). Such invest...

The Motley Fool - 3 months ago

One of the company's subsidiaries received some bad news today.

GlobeNewsWire - 4 months ago

- Caelum Biosciences, a company founded by Fortress, is collaborating with Alexion Pharmaceuticals on the studies

GlobeNewsWire - 4 months ago

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing...

Seeking Alpha - 4 months ago

Fortress Biotech reports positive data from CUTX-101.

Benzinga - 4 months ago

Fortress Biotech (NASDAQ: FBIO) shares are trading higher on Friday after the company announced positive topline clinical efficacy results for CUTX-101 Copper Histidinate in the treatment of M...

GlobeNewsWire - 4 months ago

Statistically Significant Improvement in the Primary Endpoint of Overall Survival in Menkes Disease Patients who Received Early Treatment with CUTX-101, Compared to an Untreated Historical Con...

About FBIO

Fortress Biotech develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ximino to treat inflammatory lesions of severe acne vulgaris. It also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial product that reduces amyloid deposits in the tissues and organs; MB-102, a chimeric a... [Read more...]

Industry
Biotechnology
Founded
2006
CEO
Lindsay Rosenwald
Employees
93
Stock Exchange
NASDAQ
Ticker Symbol
FBIO
Full Company Profile

Financial Performance

In 2019, FBIO's revenue was $36.63 million, an increase of 36.26% compared to the previous year's $26.88 million. Losses were -$39.96 million, -52.51% less than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for FBIO stock is "Strong Buy." The 12-month stock price forecast is 8.92, which is an increase of 151.98% from the latest price.

Price Target
$8.92
(151.98% upside)
Analyst Consensus: Strong Buy